The efficacy and safety of Femoston combined with Baoqing granules for kidney Yin deficiency in perimenopausal women: a randomized, double-blind, placebo-controlled trial - Takeaways - MDSpire

The efficacy and safety of Femoston combined with Baoqing granules for kidney Yin deficiency in perimenopausal women: a randomized, double-blind, placebo-controlled trial

  • By

  • Chun Li

  • Hong-yan Lei

  • Ruo-lan Wang

  • Jing-bo Zhang

  • Zhi-man Huang

  • Hong-ping Shen

  • Yu-lin Luo

  • Tao Ye

  • Yong-zhou Wang

  • Yuan Yuan

  • April 15, 2026

  • 0 min

Share

  • 1

    The study evaluated the safety and effectiveness of Femoston combined with Baoqing Granules for treating kidney Yin deficiency in perimenopausal women.

  • 2

    Participants receiving Baoqing Granules showed greater short-term improvements in menopausal symptoms compared to those receiving placebo.

  • 3

    Primary outcomes included the Modified Kupperman Menopausal Index and TCM syndrome scores, with secondary outcomes assessing quality of life and psychological well-being.

  • 4

    Liver and kidney functions remained normal, and only one mild adverse event was reported, indicating acceptable tolerability of the treatment.

  • 5

    The findings support Baoqing Granules as a complementary therapy for perimenopausal symptoms, but further long-term studies are needed to confirm benefits and safety.

Original Source(s)

The efficacy and safety of Femoston combined with Baoqing granules for kidney Yin deficiency in perimenopausal women: a randomized, double-blind, placebo-controlled trial

  • by Chun Li, Hong-yan Lei, Ruo-lan Wang, Jing-bo Zhang, Zhi-man Huang, Hong-ping Shen, Yu-lin Luo, Tao Ye, Yong-zhou Wang, Yuan Yuan

  • April 15, 2026

Related Content

Sex hormones and functional gastrointestinal disorders in menopausal women

Integrative approaches to healthy aging in postmenopausal women: the synergistic benefits of exercise combined with functional foods and dietary supplements

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant